Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. (Q39122506)
Jump to navigation
Jump to search
scientific article published on 19 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. |
scientific article published on 19 July 2013 |
Statements
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models (English)
Sylvia Herter
Frank Herting
Olaf Mundigl
Inja Waldhauer
Tina Weinzierl
Tanja Fauti
Gunter Muth
Doris Ziegler-Landesberger
Erwin Van Puijenbroek
Sabine Lang
Lina Reslan
Christian A Gerdes
Thomas Friess
Ute Baer
Helmut Burtscher
Michael Weidner
Pablo Umana
Gerhard Niederfellner
Marina Bacac
Christian Klein